ASCO presentation: A phase II study of tivantinib (ARQ-197) in second-line liver cancer.What we know already: Top-line data from this phase II study were released in January. Liver cancer patients who progressed after first-line therapy were randomized 2:1 to receive tivantinib or a placebo. The study met its primary endpoint with tivantinib demonstrating a 56% improvement in time to tumor regrowth compared to the placebo. Key questions: Tivantinib dose was reduced mid-study due to reports of low blood cell counts in some patients. The ASCO presentation will provide details on how each tivantinib dose performed. Key secondary endpoints in the study, most notably overall survival, will also be presented.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts